VEGFA

Ligand id: 5085

Name: VEGFA

Species: Human

References
1. Anderson CR, Rychak JJ, Backer M, Backer J, Ley K, Klibanov AL. (2010)
scVEGF microbubble ultrasound contrast agents: a novel probe for ultrasound molecular imaging of tumor angiogenesis.
Invest Radiol, 45 (10): 579-85. [PMID:20733505]
2. Baca M, Chen Y M-Y, Lowman HB, Presta LG, Wells JA. (1998)
Anti-vegf antibodies.
Patent number: WO1998045331. Assignee: Genentech Inc,. Priority date: 07/04/1997. Publication date: 15/10/1998.
3. Backer MV, Backer JM. (2001)
Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins.
Bioconjug. Chem., 12 (6): 1066-73. [PMID:11716701]
4. Baehner M, Imhof-Jung S, Kavlie A, Kettenberger H, Klein C, Thomas J, Schaefer W, Stubenrauch K-G, Thomas M. (2015)
Bispecific, bivalent anti-VEGF/anti-ANG-2 antibodies.
Patent number: US8945552 B2. Assignee: Hoffmann-La Roche Inc.. Priority date: 26/03/2010. Publication date: 03/02/2015.
5. Borras L, Urech D, Gunde T. (2013)
Stable and soluble antibodies inhibiting VEGF.
Patent number: US8349322 B2. Assignee: ESBATech, an Alcon Biomedical Research Unit, LLC.. Priority date: 25/06/2008. Publication date: 08/01/2013.
6. Campochiaro PA, Channa R, Berger BB, Heier JS, Brown DM, Fiedler U, Hepp J, Stumpp MT. (2013)
Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study.
Am. J. Ophthalmol., 155 (4): 697-704, 704.e1-2. [PMID:23218689]
7. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, Zhu M. (2014)
Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.
Ophthalmology, 121 (1): 188-92. [PMID:24144450]
8. Chu QS. (2009)
Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors.
Expert Opin Biol Ther, 9 (2): 263-71. [PMID:19236257]
9. Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. (2004)
Pegaptanib for neovascular age-related macular degeneration.
N. Engl. J. Med., 351 (27): 2805-16. [PMID:15625332]
10. King C, Hristova K. (2019)
Direct measurements of VEGF-VEGFR2 binding affinities reveal the coupling between ligand binding and receptor dimerization.
J. Biol. Chem., 294 (23): 9064-9075. [PMID:31023826]
11. Nimjee SM, Rusconi CP, Sullenger BA. (2005)
Aptamers: an emerging class of therapeutics.
Annu. Rev. Med., 56: 555-83. [PMID:15660527]
12. Tang PA, Moore MJ. (2013)
Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations.
Therap Adv Gastroenterol, 6 (6): 459-73. [PMID:24179482]
13. Vempati P, Popel AS, Mac Gabhann F. (2014)
Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.
Cytokine Growth Factor Rev., 25 (1): 1-19. [PMID:24332926]
14. Zachary IC. (2011)
How neuropilin-1 regulates receptor tyrosine kinase signalling: the knowns and known unknowns.
Biochem. Soc. Trans., 39 (6): 1583-91. [PMID:22103491]